Nitroxides as Protectors against Oxidative StressOur laboratory was first to demonstrate that nitroxides (such as Tempol) are effective antioxidants and protectors against ionizing radiation damage. The mechanism(s) for nitroxide-mediated protection against oxidative stress include superoxide dismutase- and catalase-like activity and radical-radical reactions. However, more recent studies have focused on whether nitroxide treatment impacts gene expression. Cells treated with non-toxic concentrations of several different nitroxide analogues; including a nitroxide incapable of cellular entry (and protection) all exhibit similar patterns of gene expression. A comparison was made of gene expression profiles for MCF7 cells exposed to nitroxides and various forms of oxidative stress (hydrogen peroxide, superoxide, nitric oxide, and ionizing radiation). Interestingly, a small subset of genes related to inflammatory responses was up regulated for all forms of oxidative stress; whereas, the same genes for nitroxide treatment were all down regulated. These studies will provide additional insight into the radio-protective properties of nitroxides, particularly with respect to the differential radioprotection of Tempol toward normal tissues as opposed to tumor. Tempol administered 10 min prior to fractionated radiation treatment does not protect SCC and HT-29 tumor growth; whereas, Tempol administered in the same fashion protects against radiation-induced salivary gland damage. Our lab has made a recent major advancement that can be used to explain this difference. Nitroxides can be used as functional MRI contrast probes allowing for determination of tissue redox status. We have shown that Tempol is reduced in tumor tissue to the non-radioprotective hydroxylamine faster than in salivary gland tissue. Nitroxide based MRI studies thus have the potential to guide to appropriate timing of nitroxide administration to yield maximal radioprotection of normal tissues without protection of tumor. In collaboration with the Radiation Oncology Branch a Phase I clinical trail (first in humans) has been submitted to evaluate Tempol as a functional MRI contrast probe. Since nitroxides readily penetrate cell membranes and are potent antioxidants, they may be of use in other areas of medical research such as ischemia/reperfusion injury studies, prevention of cataracts, inflammatory processes, and aging. Additionally, nitroxide based MRI evaluation may clinical utility in defining the above-mentioned conditions. Lastly, we continue to seek the mechanism of how long-term administration of Tempol (in the food or drinking water) results in dramatic weight reduction and a decrease in spontaneous tumor incidence in mice. Tempol administration also delays the onset of tumors in Atm and p53 deficient mice. We have recently found that systemic levels of IGF-1 are decreased in Tempol treated animals, similar to that observed in caloric restricted animals. These studies will hopefully enable us to better understand the complex cellular/molecular mechanisms of nitroxides that trigger responses important in the antioxidant properties of nitroxides as well as those related to weight and the chemopreventive findings.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC006387-19
Application #
7331390
Study Section
(RBB)
Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Simone, Nicole L; Soule, Benjamin P; Ly, David et al. (2009) Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 4:e6377
Ghosh, Manik C; Tong, Wing-Hang; Zhang, Deliang et al. (2008) Tempol-mediated activation of latent iron regulatory protein activity prevents symptoms of neurodegenerative disease in IRP2 knockout mice. Proc Natl Acad Sci U S A 105:12028-33
Soule, Benjamin P; Hyodo, Fuminori; Matsumoto, Ken-Ichiro et al. (2007) The chemistry and biology of nitroxide compounds. Free Radic Biol Med 42:1632-50
Soule, Benjamin P; Hyodo, Fuminori; Matsumoto, Ken-Ichiro et al. (2007) Therapeutic and clinical applications of nitroxide compounds. Antioxid Redox Signal 9:1731-43
Tsai, Mong-Hsun; Cook, John A; Chandramouli, Gadisetti V R et al. (2007) Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 67:3845-52
Patel, Kinjal; Chen, Yifan; Dennehy, Kathryn et al. (2006) Acute antihypertensive action of nitroxides in the spontaneously hypertensive rat. Am J Physiol Regul Integr Comp Physiol 290:R37-43
Thomas, Douglas D; Ridnour, Lisa A; Espey, Michael Graham et al. (2006) Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem 281:25984-93
Matsumoto, Ken-Ichiro; Hyodo, Fuminori; Matsumoto, Atsuko et al. (2006) High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res 12:2455-62
Okajo, Aya; Matsumoto, Ken-ichiro; Mitchell, James B et al. (2006) Competition of nitroxyl contrast agents as an in vivo tissue redox probe: comparison of pharmacokinetics by the bile flow monitoring (BFM) and blood circulating monitoring (BCM) methods using X-band EPR and simulation of decay profiles. Magn Reson Med 56:422-31
Van Waes, Carter; Chang, Angela A; Lebowitz, Peter F et al. (2005) Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63:1400-12

Showing the most recent 10 out of 20 publications